Sugi Predict

Sugi Predict / Compounds / SCHEMBL6735552

SCHEMBL6735552

SCHEMBL6735552

Cc1oc(Cc2ccc3ccccc3c2)c(C(=O)c2cc(C(C)C)c(O)c(C(C)C)c2)c1C

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GABRA1 P14867 1/20 0.46
▸ GABRB1 P18505 1/20 0.46
▸ NQO1 P15559 3/20 0.40
▸ BCL2 P10415 2/20 0.38
▸ MCL1 Q07820 2/20 0.38
▸ TBXA2R P21731 1/20 0.37
▸ PTGER4 P35408 1/20 0.37
▸ PTGFR P43088 1/20 0.37
▸ PTGER3 P43115 1/20 0.37
▸ PTGER2 P43116 1/20 0.37
▸ PTGDR Q13258 1/20 0.37
▸ CES2 O00748 1/20 0.36
▸ TDP1 Q9NUW8 1/20 0.35
▸ PDE1A P54750 1/20 0.35
▸ PDE1B Q01064 1/20 0.35
▸ PDE1C Q14123 1/20 0.35
▸ LMNA P02545 1/20 0.35
▸ GAA P10253 1/20 0.35
▸ HTT P42858 1/20 0.35
▸ CETP P11597 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6736985 0.89 GABRA1 (0.53) GABRA1GABRB1BCL2MCL1LMNA
SCHEMBL6730814 0.89 PIN1 (0.40) NQO1TBXA2RPTGER4PTGFRPTGER3
SCHEMBL6730807 0.84 GABRA1 (0.42) GABRA1GABRB1BCL2MCL1TBXA2R
SCHEMBL6734499 0.84 GABRA1 (0.42) GABRA1GABRB1BCL2MCL1TBXA2R
SCHEMBL6731106 0.80 GABRA1 (0.46) GABRA1GABRB1BCL2MCL1TBXA2R
SCHEMBL6740174 0.79 PTPN1 (0.45) MCL1
SCHEMBL6731441 0.77 GLRA1 (0.43) GABRA1GABRB1LMNAGAAHTT
SCHEMBL6738738 0.73 CYP2C19 (0.38) LMNACYP2C19
SCHEMBL6735422 0.73 CYP2C19 (0.36) LMNAALOX5CYP2C9CYP2C19
SCHEMBL6734693 0.72 CYP2C9 (0.43) NQO1TBXA2RLMNAHTR2AHTR2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6683107-B2 THERAPY OF METABOLISM DISORDERS WYETH 2004-01-27 — — US disclosed
US-20030073709-A1 Furans, benzofurans, and thiophenes useful in the treatment of insulin resistance and hyperglycemia WYETH 2003-04-17 — — US disclosed
US-6451845-B1 ANTIDIABETIC AGENTS WYETH 2002-09-17 — — US disclosed
US-20020035272-A1 Furans, benzofurans, and thiophenes useful in the treatment of insulin resistance and hyperglycemia AMERICAN HOME PRODUCTS CORPORATION 2002-03-21 — — US disclosed
US-6248764-B1 ANTIDIABETIC AGENT; HYPOGLYCEMIC AGENT AMERICAN HOME PRODUCTS CORPORATION 2001-06-19 — — US disclosed
US-6103708-A USEFUL IN TREATING METABOLIC DISORDERS RELATED TO INSULIN RESISTANCE OR HYPERGLYCEMIA AMERICAN HOME PRODUCTS CORPORATION (US) 2000-08-15 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030073709-A1 Furans, benzofurans, and thiophenes useful in the treatment of insulin resistance and hyperglycemia GPR119, INSR, FFAR3 GABRA1 549/4885GABRB1 174/4885NQO1 4253/4885
US-20020035272-A1 Furans, benzofurans, and thiophenes useful in the treatment of insulin resistance and hyperglycemia INSR, GPR119, FFAR3 GABRA1 682/4885GABRB1 215/4885NQO1 4004/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.